Navigation Links
UWM research offers hope for treatment of cocaine addiction
Date:7/15/2011

New discoveries by researchers at the University of Wisconsin-Milwaukee (UWM) offer potential for development of a first-ever pharmacological treatment for cocaine addiction.

A common beta blocker, propranolol, currently used to treat people with hypertension and anxiety, has shown to be effective in preventing the brain from retrieving memories associated with cocaine use in animal-addiction models, according to Devin Mueller, UWM assistant professor of psychology and a co-author with James Otis of the research.

This is the first time that a therapeutic treatment has been shown to block the retrieval of memories associated with drug addiction, a major reason many addicts experience relapse, says Mueller.

The research is published in the August issue of the journal Neuropsychopharmacology ("Inhibition of β-Adrenergic Receptors Induces a Persistent Deficit in Retrieval of a Cocaine-Associated Memory Providing Protection against Reinstatement.")

Cocaine is one of the worst drug addictions to kick, with about 80 percent of those trying to quit experiencing a relapse within six months.

"Right now, there are no FDA-approved medications that are known to successfully treat cocaine abuse," says Mueller, "only those that are used to treat the symptoms of cocaine withdrawal, which are largely ineffective at preventing relapse."

The effects of propranolol were long-lasting and could be permanent, he says, even without subsequent doses and even in the presence of stimuli known to induce relapse.

Currently, "exposure therapy" is used to help recovering addicts suppress their drug-seeking behavior. In this therapy, the patient is repeatedly exposed to stimuli that provoke cravings but do not satisfy them. Done repeatedly over time, the patient experiences less craving when presented with those stimuli.

The success of exposure therapy, however, is limited. Combining therapy with the use of propranolol, says Mueller, would boost the effectiveness of the treatment.

Propranolol was chosen for the memory study because it has been used before to ease some withdrawal symptoms experienced by recovering cocaine addicts. Those using the drug were able to continue exposure therapy for longer periods than those without the drug.

But Mueller adds that propranolol has never been tested for use with memory extinction before.

In order to develop a drug treatment for overcoming relapse, the next step in the research is to determine where in the brain propranolol acts to mediate the retrieval of cocaine-associated memories.


'/>"/>

Contact: Devin Mueller
devinm@uwm.edu
414-732-1614
University of Wisconsin - Milwaukee
Source:Eurekalert

Related biology news :

1. Research links telomere length to emphysema risk
2. The first studies utilizing the Collaborative Cross mice are published in Genome Research
3. Wood products part of winning carbon-emissions equation, researchers say
4. IRCM researchers uncover a new piece of the puzzle in the development of our nervous system
5. Notre Dame research reveals brain network connections
6. Cancer data not readily available for future research
7. Research provides insight into new drug resistance in hospital microbes
8. TUM researchers discover a new switch in resistance to plant diseases
9. BUSM researchers urge awareness of dietary iodine intake in postpartum Korean-American women
10. Researchers study pesticide pathways into the atmosphere
11. Johns Hopkins researchers identify new genetic risk factor for sudden cardiac death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... - Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle ... around 15.1% over the next decade to reach approximately $1,580 million ... estimates and forecasts for all the given segments on global as ...
(Date:3/22/2017)... March 21, 2017 Vigilant Solutions , ... law enforcement agencies, announced today the appointment of retired ... of public safety business development. Mr. Sheridan ... experience, including a focus on the aviation transportation sector, ... recent position, Mr. Sheridan served as the Aviation Liaison ...
(Date:3/9/2017)... , March 9, 2017 4Dx has publicly ... Lung Imaging Workshop at the University of Pennsylvania. Founder ... to deliver the latest data to world leaders in ... brings together leaders at the forefront of the industry ... imaging. "The quality of the imaging ...
Breaking Biology News(10 mins):
(Date:4/27/2017)... and RESEARCH TRIANGLE PARK, N.C. ... (NASDAQ: UTHR ) today announced that its ... $250 million of the company,s common stock. This program ... December 31, 2017. Purchases may be made in the ... transactions from time to time as determined by United ...
(Date:4/27/2017)... Baltimore, MD (PRWEB) , ... April 27, 2017 ... ... analytics solutions provider for digital pathology, today announced their digital pathology technology has ... Using images provided by five medical centers in The Netherlands as part of ...
(Date:4/27/2017)... ... April 27, 2017 , ... This month ... (eConsent) solution that simplifies research studies, accelerates study startup, and improves participant engagement. ... Consent™ is the first and only IRB-integrated eConsent solution . , “Our ...
(Date:4/27/2017)... Ca (PRWEB) , ... April 27, 2017 , ... ... from a practicing internist, who will review how testing for 1,25-Dihydroxyvitamin D can ... prompt ordering of 25-OH-vitamin D and 1,25 dihydroxyvitamin D. , Dr. Gregory Plotnikoff, ...
Breaking Biology Technology: